HOME > BUSINESS
BUSINESS
- Eisai/UCL’s Anti-Tau Antibody Heading into PI for Alzheimer’s Disease
December 7, 2018
- U3-1402 Racks Up 42.9% Response Rate in Breast Cancer Study: Daiichi Sankyo
December 7, 2018
- Teva Takeda Yakuhin Applies for Pediatric Use for Blopress Based on Information in Public Domain
December 7, 2018
- Fuji Yakuhin, Pfizer to Terminate Copromotion for Topiloric in January
December 7, 2018
- Pfizer to Transfer Antiepileptic Agent Gabapen to Fuji Pharma
December 7, 2018
- Chugai Sues Alexion Japan over Soliris Successor ALXN1210 after US
December 6, 2018
- Amicus Aims to Expand Rare and Intractable Disease Pipeline in Japan
December 6, 2018
- Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold
December 6, 2018
- Takeda Shareholders OK £46 Billion Shire Takeover
December 5, 2018
- Hemlibra Approved in Taiwan for Treatment of Hemophilia A with Inhibitors: Chugai
December 5, 2018
- Gilteritinib Shows High Response Rate in Previously Untreated AML Patients in PI: Astellas
December 5, 2018
- Elmed Eisai to Be Renamed “Elmed”, Move Headquarters to Toyama
December 5, 2018
- Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle
December 4, 2018
- Takeda Inks US$3.7 Billion Loan Accord with JBIC
December 4, 2018
- Ninlaro Shows 39% Improvement in PFS in Post-Transplant Multiple Myeloma Patients: Takeda
December 4, 2018
- Astellas Launches Sakigake-Designated AML Drug Xospata
December 4, 2018
- Fujifilm Toyama Chemical Licenses Cancer “Theragnostic” Agent to Novartis Subsidiary
December 4, 2018
- MSD Japan Chief Voices High Hopes for Keytruda Label Expansions
December 3, 2018
- With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman
December 3, 2018
- Lilly Launches Breast Cancer Drug Verzenio
December 3, 2018
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
